Lung cancer immune cell trial halted after just 2 patients

NCT ID NCT06235242

Terminated Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early trial tested a treatment that takes immune cells from a patient's own tumor, grows them in a lab, and gives them back along with an immune-boosting drug called teraplizumab. The goal was to see if this combination is safe and tolerable for people with advanced non-small cell lung cancer. Only 2 patients were enrolled before the study was terminated, so we have very limited information.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous tumor-infiltrating lymphocytes (GT201) plus teraplizumab
What this could lead to: If it works, this could point toward a new treatment option for advanced non-small cell lung cancer using a patient's own immune cells.
What could go wrong: This was a very small, early safety trial with only 2 participants and has already been terminated, so results are limited and may not apply to others. Risks include severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Beijing Gobroad Hospital

Beijing, Beijing Municipality, China
Shanghai East Hospital

Shanghai, Shanghai Municipality, 200120, China
Shanghai GoBroad Cancer Hospital

Shanghai, Shanghai Municipality, 200120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.